Northern Trust Corp Affimed N.V. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.66 - $1.29 $3,946 - $7,712	-5,979 Reduced 0.61%	981,320 $735,000
Q4 2022 Feb 13, 2023	BUY	$1.1 - $2.45 $12,819 - $28,552	11,654 Added 1.19%	987,299 $1.22 Million
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $27,914 - $47,283	-14,242 Reduced 1.44%	975,645 $2.01 Million
Q2 2022 Aug 12, 2022	BUY	$2.27 - $4.86 $329,018 - $704,418	144,942 Added 17.15%	989,887 $2.74 Million
Q1 2022 May 13, 2022	SELL	$3.69 - $5.65 $182,880 - $280,019	-49,561 Reduced 5.54%	844,945 $3.69 Million
Q4 2021 Feb 08, 2022	BUY	$5.37 - $7.07 $85,957 - $113,169	16,007 Added 1.82%	894,506 $4.94 Million
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $307,132 - $416,346	-55,439 Reduced 5.94%	878,499 $5.43 Million
Q2 2021 Aug 13, 2021	SELL	$7.78 - $11.4 $169,432 - $248,269	-21,778 Reduced 2.28%	933,938 $7.94 Million
Q1 2021 May 12, 2021	BUY	$5.12 - $8.48 $850,954 - $1.41 Million	166,202 Added 21.05%	955,716 $7.56 Million
Q4 2020 Feb 11, 2021	BUY	$3.16 - $7.03 $127,480 - $283,604	40,342 Added 5.38%	789,514 $4.6 Million
Q3 2020 Nov 16, 2020	BUY	$3.26 - $4.73 $24,870 - $36,085	7,629 Added 1.03%	749,172 $2.54 Million
Q2 2020 Aug 14, 2020	BUY	$1.58 - $4.63 $42,132 - $123,463	26,666 Added 3.73%	741,543 $3.42 Million
Q1 2020 May 14, 2020	BUY	$1.44 - $3.02 $70,158 - $147,137	48,721 Added 7.31%	714,877 $1.13 Million
Q4 2019 Feb 14, 2020	BUY	$2.25 - $3.07 $239,438 - $326,700	106,417 Added 19.01%	666,156 $1.83 Million
Q3 2019 Nov 13, 2019	BUY	$2.67 - $3.65 $1.36 Million - $1.85 Million	507,528 Added 972.07%	559,739 $1.65 Million
Q2 2019 Aug 13, 2019	BUY	$2.6 - $4.21 $135,748 - $219,808	52,211 New	52,211 $150,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account